FDA Grants Efanesoctocog Alfa Breakthrough Therapy Designation for Hemophilia A

Paris and Stockholm– June 1, 2022– The United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to efanesoctocog alfa (BIVV001) for the treatment of people with hemophilia A, a rare and...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials